iBio, Inc. and GE Healthcare form new global alliance

iBio, Inc. and GE Healthcare form new global alliance
--Companies to commercialize plant-based technologies for biopharmaceutical and vaccine manufacture --Innovative approach offers potential to reduce costs, increase manufacturing flexibility

NEWARK, Del. and CHALFONT ST GILES, England, July 26, 2012  -- iBio, Inc. (nyse mkt:IBIO), and GE Healthcare, the healthcare business of GE GE +0.15% , announced today a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines. The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio's innovative plant-based vaccine manufacturing platform, iBioLaunch(TM), with GE Healthcare's world-class capabilities in start-to-finish technologies for biopharmaceutical manufacturing. iBio's research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB) will continue to play a key role in advancing the iBioLaunch platform. Financial terms were not disclosed.

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.